<DOC>
	<DOCNO>NCT02955381</DOCNO>
	<brief_summary>Randomized , double-blind , placebo-controlled , research pilot study . 30 subject age 22-55 year old skin type ask sign inform consent form prior study procedure . Subjects must least 1 3 acne scar ≥3 mm ≤ 10 mm locate cheek forehead . Subjects receive one treatment ( Restylane® Silk Placebo ) scar day 0 , Month 1 ( 2 total treatment per scar study ) . Subjects ask come 10 visit : Screening visit ( 35 day prior Baseline ) , Baseline ( Day 0 ) , Day 7 , Day 14 , Month 1 , Month 2 , Month 3 , Month 4 , Month 5 , Month 6 ( study exit visit ) . The treatment area evaluate visit unblinded investigator regard erythema , bruising , inflammation , itching , stinging/burning , brightness , fullness , smoothness , clarity . Safety adverse event capture visit unblinded investigator .</brief_summary>
	<brief_title>Restylane Silk Acne Scar Efficacy Evaluation Study</brief_title>
	<detailed_description>Randomized , double-blind , placebo-controlled , research pilot study . 30 subject age 22-55 year old skin type ask sign inform consent form prior study procedure . Subjects must least 1 3 acne scar ≥3 mm ≤ 10 mm locate cheek forehead . Subjects receive one treatment ( Restylane® Silk Placebo ) scar day 0 , Month 1 ( 2 total treatment per scar study ) . Subjects ask come 10 visit : Screening visit ( 35 day prior Baseline ) , Baseline ( Day 0 ) , Day 7 , Day 14 , Month 1 , Month 2 , Month 3 , Month 4 , Month 5 , Month 6 ( study exit visit ) . The blinded investigator evaluate target scar use Acne Scar Rating Scale ( ASRS ) , rate target acne scar regard treatment effect -5 ( `` Markedly bad '' ) , 0 ( `` Neutral Improvement '' ) , 5 ( Markedly Improved ( Clear nearly clear ) ) point scale , evaluate skin quality ( regard brightness , fullness , smoothness , clarity ) . Subjects give acne scar score subject VAS acne scar satisfaction scale mark 0 ( `` Not satisfied Acne Scar Day 0 '' ) 10 ( `` Extremely Satisfied Acne Scar Day 0 '' ) . The treatment area evaluate visit unblinded investigator regard erythema , bruising , inflammation , itching , stinging/burning , brightness , fullness , smoothness , clarity . The subject vital sign take , complete symptom diary ( subject experience side effect adverse event ) , complete DLQI , photo ( VECTRA 2D digital photograph ) take treatment area . Efficacy measure complete blind investigator . Safety adverse event capture visit unblinded investigator .</detailed_description>
	<mesh_term>Hyaluronic Acid</mesh_term>
	<criteria>1 . Male nonpregnant female subject acceptable form birth control age 2255 year age . 2 . Willing refrain undergoing procedure repair augment acne scar treatment area study . 3 . Female subject negative pregnancy test confirm screen acceptable form birth control . Acceptable form birth control study include oral injectable contraceptive , contraceptive patch , DepoProvera , NuvaRing , Implanon , double barrier method , IUD , sex partner , abstinence . Males require use acceptable method birth control : vasectomy , doublebarrier method , condom spermicidal lube , abstinence . 4 . Signed informed consent prior conduct study procedure . 5 . Willing refrain undergoing cosmetic procedure treatment area study . 6 . At least one acne scar locate cheek forehead ≥ 3 mm ≤ 10 mm diameter , rat ≥3 ASRS day 0 . Subjects may three qualify acne scar determine eligible treatment screening . 7 . Acne scar classify either ice pick , rolling , boxcar acne scar . 8 . ≤15 pustules/papules face time screen ≤ 2 cyst Baseline . 9 . Willing attend study visit comply protocol 1 . Subjects active cystic acne screening ( &gt; 2 nodule ) . 2 . Use antibiotic 2weeks prior screening . 3 . Use retinoids 2weeks prior screening . 4 . Use salicylic acid benzoyl peroxide 7 day prior screen . 5 . Excessive facial hair , skin condition , facial tattoo , dermatologic mark would obscure treatment area . 6 . Use Isotretinoin ( Accutane ) 6 month prior screen . 7 . Semipermanent permanent injection face 3 month prior screen . 8 . History bleed disorder . 9 . Use blood thinner ( i.e warfarin ( Coumadin ) , clopidogrel bisulfate ( Plavix ) , etc . ) 1 month prior screen . 10 . Acne scar consider postinflammatory erythematous , postinflammatory hyperpigmentation , varicella ( chicken pox ) scar , perifollicular elastolysis allow identified target acne scar . These type scar still allow present select . 11 . Acne scar locate glabella temple region . Acne scar locate region allow select target additional acne scar . As well , scar locate area allow treat study . Subjects allow acne scar locate area select evaluation treat study . 12 . Laser light ( red blue ) treatments acne 3 month prior screen . 13 . Resurfacing procedure ( CO2 , Erbium , Fraxel , etc . ) perform 6 month prior screen . 14 . Any chemical peel last 30 day prior screen . 15 . Hypersensitivity amidtype local anesthetic . 16 . Any cortisol steroid ILK injection 30 day prior screen 17 . Subjects history diabetes . 18 . Any medical condition diagnosis investigator 's opinion would disqualify research study . 19 . History abuse use alcohol drug . 20 . Participation clinical trial use investigational product past 30 day . 21 . Subjects consider health risk participation study investigator determine suitable .</criteria>
	<gender>All</gender>
	<minimum_age>22 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>